A Study to Evaluate the Safety and Efficacy of 3% LTX-109 for Nasal Decolonisation of Staphylococcus

NCT04767321 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

15

Enrollment

INDUSTRY

Sponsor class

Conditions

Nasal Decolonization of Staphylococcus Aureus

Interventions

DRUG: LTX-109 gel, 3% w/w
DRUG: Placebo

Sponsor

Pharma Holdings AS

Collaborators

[object Object]